SANOFI-ADR (SNY) Stock Fundamental Analysis
USA - NASDAQ:SNY - US80105N1054 - ADR
47.01 USD
-0.63 (-1.32%)
47.11 USD
+0.1 (+0.21%)
We assign a fundamental rating of 6 out of 10 to SNY. SNY was compared to 196 industry peers in the Pharmaceuticals industry. While SNY belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on SNY. Finally SNY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year SNY was profitable.
SNY had a positive operating cash flow in the past year.
SNY had positive earnings in each of the past 5 years.
Each year in the past 5 years SNY had a positive operating cash flow.
1.2 Ratios
SNY's Return On Assets of 11.05% is amongst the best of the industry. SNY outperforms 92.35% of its industry peers.
SNY has a better Return On Equity (19.73%) than 91.84% of its industry peers.
With an excellent Return On Invested Capital value of 13.84%, SNY belongs to the best of the industry, outperforming 92.35% of the companies in the same industry.
SNY had an Average Return On Invested Capital over the past 3 years of 7.31%. This is significantly below the industry average of 15.28%.
The last Return On Invested Capital (13.84%) for SNY is above the 3 year average (7.31%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROIC | 13.84% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
1.3 Margins
With an excellent Profit Margin value of 20.35%, SNY belongs to the best of the industry, outperforming 93.37% of the companies in the same industry.
In the last couple of years the Profit Margin of SNY has grown nicely.
SNY's Operating Margin of 23.59% is amongst the best of the industry. SNY outperforms 90.31% of its industry peers.
SNY's Operating Margin has improved in the last couple of years.
SNY has a better Gross Margin (71.70%) than 79.08% of its industry peers.
SNY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% |
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
2. Health
2.1 Basic Checks
SNY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for SNY remains at a similar level compared to 1 year ago.
The number of shares outstanding for SNY remains at a similar level compared to 5 years ago.
The debt/assets ratio for SNY has been reduced compared to a year ago.
2.2 Solvency
The Debt to FCF ratio of SNY is 2.21, which is a good value as it means it would take SNY, 2.21 years of fcf income to pay off all of its debts.
SNY has a Debt to FCF ratio of 2.21. This is amongst the best in the industry. SNY outperforms 92.86% of its industry peers.
A Debt/Equity ratio of 0.21 indicates that SNY is not too dependend on debt financing.
SNY's Debt to Equity ratio of 0.21 is in line compared to the rest of the industry. SNY outperforms 46.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Altman-Z | N/A |
ROIC/WACC1.89
WACC7.32%
2.3 Liquidity
SNY has a Current Ratio of 1.27. This is a normal value and indicates that SNY is financially healthy and should not expect problems in meeting its short term obligations.
SNY has a worse Current ratio (1.27) than 74.49% of its industry peers.
SNY has a Quick Ratio of 1.27. This is a bad value and indicates that SNY is not financially healthy enough and could expect problems in meeting its short term obligations.
SNY has a worse Quick ratio (0.94) than 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 |
3. Growth
3.1 Past
The earnings per share for SNY have decreased by -2.20% in the last year.
Measured over the past 5 years, SNY shows a small growth in Earnings Per Share. The EPS has been growing by 5.10% on average per year.
Looking at the last year, SNY shows a small growth in Revenue. The Revenue has grown by 6.45% in the last year.
The Revenue has been growing slightly by 3.31% on average over the past years.
EPS 1Y (TTM)-2.2%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%-8.09%
Revenue 1Y (TTM)6.45%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-6.99%
3.2 Future
Based on estimates for the next years, SNY will show a small growth in Earnings Per Share. The EPS will grow by 6.41% on average per year.
Based on estimates for the next years, SNY will show a small growth in Revenue. The Revenue will grow by 4.04% on average per year.
EPS Next Y3.91%
EPS Next 2Y6.53%
EPS Next 3Y6.33%
EPS Next 5Y6.41%
Revenue Next Year-0.29%
Revenue Next 2Y3.32%
Revenue Next 3Y4.42%
Revenue Next 5Y4.04%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 10.56, the valuation of SNY can be described as very reasonable.
89.29% of the companies in the same industry are more expensive than SNY, based on the Price/Earnings ratio.
SNY is valuated cheaply when we compare the Price/Earnings ratio to 27.41, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 9.14, which indicates a very decent valuation of SNY.
SNY's Price/Forward Earnings ratio is rather cheap when compared to the industry. SNY is cheaper than 85.71% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of SNY to the average of the S&P500 Index (22.87), we can say SNY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.56 | ||
| Fwd PE | 9.14 |
4.2 Price Multiples
SNY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SNY is cheaper than 97.45% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, SNY is valued cheaply inside the industry as 91.84% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.7 | ||
| EV/EBITDA | 5.4 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SNY does not grow enough to justify the current Price/Earnings ratio.
SNY has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.7
PEG (5Y)2.07
EPS Next 2Y6.53%
EPS Next 3Y6.33%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.89%, SNY is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 5.74, SNY pays a better dividend. On top of this SNY pays more dividend than 96.43% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.38, SNY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.89% |
5.2 History
The dividend of SNY has a limited annual growth rate of 4.30%.
SNY has paid a dividend for at least 10 years, which is a reliable track record.
The dividend of SNY decreased in the last 3 years.
Dividend Growth(5Y)4.3%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
34.82% of the earnings are spent on dividend by SNY. This is a low number and sustainable payout ratio.
The dividend of SNY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP34.82%
EPS Next 2Y6.53%
EPS Next 3Y6.33%
47.01
-0.63 (-1.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners40.34%
Inst Owner Change-5.25%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap114.66B
Analysts80
Price Target64.8 (37.84%)
Short Float %0.23%
Short Ratio1.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.89% |
Yearly Dividend2.23
Dividend Growth(5Y)4.3%
DP34.82%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.86%
Min EPS beat(2)-2.29%
Max EPS beat(2)6.02%
EPS beat(4)2
Avg EPS beat(4)4.01%
Min EPS beat(4)-2.29%
Max EPS beat(4)14.5%
EPS beat(8)4
Avg EPS beat(8)2.17%
EPS beat(12)7
Avg EPS beat(12)2.71%
EPS beat(16)11
Avg EPS beat(16)3.44%
Revenue beat(2)0
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-1.3%
Max Revenue beat(2)-0.63%
Revenue beat(4)1
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-4.57%
Max Revenue beat(4)3.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.12%
Revenue beat(12)4
Avg Revenue beat(12)9.26%
Revenue beat(16)8
Avg Revenue beat(16)21.08%
PT rev (1m)1.34%
PT rev (3m)-0.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.62%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.9%
Revenue NY rev (1m)-0.47%
Revenue NY rev (3m)-1.8%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.56 | ||
| Fwd PE | 9.14 | ||
| P/S | 1.44 | ||
| P/FCF | 9.7 | ||
| P/OCF | 8.58 | ||
| P/B | 1.4 | ||
| P/tB | 10.51 | ||
| EV/EBITDA | 5.4 |
EPS(TTM)4.45
EY9.47%
EPS(NY)5.14
Fwd EY10.94%
FCF(TTM)4.85
FCFY10.31%
OCF(TTM)5.48
OCFY11.65%
SpS32.67
BVpS33.69
TBVpS4.47
PEG (NY)2.7
PEG (5Y)2.07
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROCE | 16.7% | ||
| ROIC | 13.84% | ||
| ROICexc | 16.48% | ||
| ROICexgc | 66.95% | ||
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% | ||
| FCFM | 14.83% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
ROICexc(3y)8.13%
ROICexc(5y)7.97%
ROICexgc(3y)35.39%
ROICexgc(5y)35.54%
ROCE(3y)8.84%
ROCE(5y)8.55%
ROICexcg growth 3Y-13.63%
ROICexcg growth 5Y-1.43%
ROICexc growth 3Y-1.55%
ROICexc growth 5Y2.05%
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
F-Score7
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Debt/EBITDA | 0.75 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 58.05% | ||
| Profit Quality | 72.91% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 | ||
| Altman-Z | N/A |
F-Score7
WACC7.32%
ROIC/WACC1.89
Cap/Depr(3y)73.02%
Cap/Depr(5y)67.36%
Cap/Sales(3y)6.35%
Cap/Sales(5y)5.97%
Profit Quality(3y)113.82%
Profit Quality(5y)104.22%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.2%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%-8.09%
EPS Next Y3.91%
EPS Next 2Y6.53%
EPS Next 3Y6.33%
EPS Next 5Y6.41%
Revenue 1Y (TTM)6.45%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-6.99%
Revenue Next Year-0.29%
Revenue Next 2Y3.32%
Revenue Next 3Y4.42%
Revenue Next 5Y4.04%
EBIT growth 1Y15.64%
EBIT growth 3Y1.33%
EBIT growth 5Y5.12%
EBIT Next Year34.08%
EBIT Next 3Y14.6%
EBIT Next 5Y9.88%
FCF growth 1Y24.23%
FCF growth 3Y-11.46%
FCF growth 5Y-0.14%
OCF growth 1Y10.87%
OCF growth 3Y-4.79%
OCF growth 5Y3.31%